These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial. Leung WK; Wu JC; Liang SM; Chan LS; Chan FK; Xie H; Fung SS; Hui AJ; Wong VW; Che CT; Sung JJ Am J Gastroenterol; 2006 Jul; 101(7):1574-80. PubMed ID: 16863563 [TBL] [Abstract][Full Text] [Related]
3. Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: a randomized, placebo-controlled, double-blind clinical trial. Brinkhaus B; Hentschel C; Von Keudell C; Schindler G; Lindner M; Stützer H; Kohnen R; Willich SN; Lehmacher W; Hahn EG Scand J Gastroenterol; 2005 Aug; 40(8):936-43. PubMed ID: 16173134 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Effect of Chang'an I Recipe ( I ) on Irritable Bowel Syndrome with Diarrhea: A Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial. Tang XD; Lu B; Li ZH; Wei W; Meng LN; Li BS; Tang ZP; Gao R; Wang FY; Lu F; Bian LQ; Zhao YP; Wang P; Zhang YQ Chin J Integr Med; 2018 Sep; 24(9):645-652. PubMed ID: 27487786 [TBL] [Abstract][Full Text] [Related]
5. Randomised clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome. Chen M; Tang TC; Wang Y; Shui J; Xiao XH; Lan X; Yu P; Zhang C; Wang SH; Yao J; Zheng H; Huang DQ Aliment Pharmacol Ther; 2018 Jul; 48(2):160-168. PubMed ID: 29856472 [TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome. Zakko S; Barton G; Weber E; Dunger-Baldauf C; Rühl A Aliment Pharmacol Ther; 2011 Jun; 33(12):1311-21. PubMed ID: 21507028 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and indication optimization of Chinese medicine (Tiao-Chang Ke-Min granules) for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial. Li Q; Zhang BP; Huang SG; Ouyang WW; Xie JH; Wen ZH; Yang XB Trials; 2018 Jul; 19(1):367. PubMed ID: 29996882 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial. Bensoussan A; Kellow JE; Bourchier SJ; Fahey P; Shim L; Malcolm A; Boyce P Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1946-54.e1. PubMed ID: 26133902 [TBL] [Abstract][Full Text] [Related]
12. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995 [TBL] [Abstract][Full Text] [Related]
13. [Treating irritable bowel syndrome with diarrhea patients by yigan fupi decoction: a randomized controlled trial]. Chen MX; Chen JX; Xia L; Fu R; Lu Z Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Jun; 34(6):656-60. PubMed ID: 25046944 [TBL] [Abstract][Full Text] [Related]
14. Post-marketing Re-evaluation of Tongxiening Granules () in Treatment of Diarrhea-Predominant Irritable Bowel Syndrome: A Multi-center, Randomized, Double-Blind, Double-Dummy and Positive Control Trial. Tang XD; Zhang SS; Hou XH; Li ZH; Chen SN; Feng PM; Yang XN; Li HZ; Wu JQ; Xia PJ; Yang XJ; Zhou HJ; Wang HY; Ai YW; Li K Chin J Integr Med; 2019 Dec; 25(12):887-894. PubMed ID: 31292845 [TBL] [Abstract][Full Text] [Related]
15. Effect of herbal extract granules combined with otilonium bromide on irritable bowel syndrome with diarrhoea: a study protocol for a randomised controlled trial. Kim JI; Kim P; Lee JH; Kim YJ; Yang NR; Baeg MK; Choi JS; Kim HJ; Kim J; Sunwoo YY; Lee JH; Ha H; Park TY BMJ Open; 2017 Dec; 7(11):e018362. PubMed ID: 29196484 [TBL] [Abstract][Full Text] [Related]
16. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. Whitehead WE; Duffy K; Sharpe J; Nabata T; Bruce M Aliment Pharmacol Ther; 2017 Jan; 45(1):14-26. PubMed ID: 27910150 [TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Nyhlin H; Bang C; Elsborg L; Silvennoinen J; Holme I; Rüegg P; Jones J; Wagner A Scand J Gastroenterol; 2004 Feb; 39(2):119-26. PubMed ID: 15000272 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of Gelsectan for diarrhoea-predominant irritable bowel syndrome: A randomised, crossover clinical trial. Trifan A; Burta O; Tiuca N; Petrisor DC; Lenghel A; Santos J United European Gastroenterol J; 2019 Oct; 7(8):1093-1101. PubMed ID: 31662866 [TBL] [Abstract][Full Text] [Related]
19. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433 [TBL] [Abstract][Full Text] [Related]
20. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Garsed K; Chernova J; Hastings M; Lam C; Marciani L; Singh G; Henry A; Hall I; Whorwell P; Spiller R Gut; 2014 Oct; 63(10):1617-25. PubMed ID: 24334242 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]